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and broader impact of health technologies is produced in the most efficient way for those
who use, manage, and work in the National Health Service in England and Wales. Access
to the full reports can be made free of charge on the HTA website 〈http://www.ncchta.org
http://www.ncchta.org〉 A fully searchable CD-ROM containing the full text of all HTA
reports is also available via the HTA website free of charge worldwide. Printed versions of
the reports cost £20 (plus post and packing: free in the UK; £2 in Europe; £3 for Rest of
the world). See website for details.
Cost–benefit evaluation of routine
influenza immunization in people 65–74
years of age
S. Allsup, M. Gosney, A. Haycox, University of Liverpool; and
M. Regan, Liverpool Health Authority
Objectives: This study aimed to determine the cost-
effectiveness of influenza vaccination in people 65–74 years
of age in the absence of comorbidity.
Design: Primary research: randomized controlled trial.
Setting: Primary care.
Participants: People without risk factors for influenza or con-
traindications to vaccination were identified from twenty gen-
eral practitioner (GP) practices in Liverpool in September
1999 and invited to participate in the study. There were 5,875
of 9,727 (60.4 percent) people 65–74 years of age identified
as potentially eligible, and of these, 729 (12 percent) were
randomized.
Intervention: Participants were randomized to receive either
influenza vaccine or placebo (ratio, 3:1), with all individuals
receiving pneumococcal vaccine unless administered in the
previous 10 years. Of the 729 people randomized, 552 re-
ceived vaccine and 177 received placebo; 726 individuals
were administered pneumococcal vaccine.
Main outcome measures and methodology of economic
evaluation: GP attendance with influenza-like illness (ILI) or
pneumonia (primary outcome measure); or any respiratory
symptoms; hospitalization with a respiratory illness; death;
participant self-reported ILI; quality of life (QoL) measures
at 2, 4, and 6 months poststudy vaccination; adverse reac-
tions 3 days after vaccination. A cost-effectiveness analysis
was undertaken to identify the incremental cost associated
with the avoidance of episodes of influenza in the vaccination
population, and an impact model was used to extrapolate the
cost-effectiveness results obtained from the trial to assess
their generalizability throughout the National Health Service
(NHS).
Results: In England and Wales, weekly consultations for
influenza and ILI remained at baseline levels (less than
50 per 100,000 population) until week 50/1999 and then in-
creased rapidly, peaking during week 2/2000 with a rate of
231/100,000. This rate fell within the range of “higher than
expected seasonal activity” of 200–400/100,000. Rates then
quickly declined, returning to baseline levels by week 5/2000.
The predominant circulating strain during this period was in-
fluenza A (H3N2). Five (0.9 percent) people in the vaccine
group were diagnosed by their GP with an ILI compared with
two (1.1 percent) in the placebo group [relative risk (RR), 0.8;
95 percent confidence interval (CI) = 0.16 to 4.1]. No partici-
pants were diagnosed with pneumonia by their GP, and there
were no hospitalizations for respiratory illness in either group.
Significantly fewer vaccinated individuals self-reported a sin-
gle ILI (4.6 percent vs 8.9 percent, RR, 0.51; 95 percent CI
for RR, 0.28 to 0.96). There was no significant difference in
any of the QoL measurements over time between the two
groups. Reported systemic side-effects showed no signifi-
cant differences between groups. Local side-effects occurred
with a significantly increased incidence in the vaccine group
(11.3 percent vs 5.1 percent, P = 0.02). Each GP consulta-
tion avoided by vaccination was estimated from trial data to
generate a net NHS cost of £174.
Conclusions: No difference was seen between groups for
the primary outcome measure, although the trial was under-
powered to demonstrate a true difference. Vaccination had no
significant effect on any of the QoL measures used, although
vaccinated individuals were less likely to self-report ILI. The
analysis did not suggest that influenza vaccination in healthy
people 65–74 years of age would lead to lower NHS costs.
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Future research should look at ways to maximize vaccine
uptake in people at greatest risk from influenza and also the
level of vaccine protection afforded to people from different
age and socioeconomic populations.
Lowering blood pressure to prevent
myocardial infarction and stroke: A new
preventive strategy
M. Law, N. Wald, and J. Morris, Wolfson Institute of Preventive
Medicine, Queen Mary’s School of Medicine and Dentistry
Objectives: This study aimed to investigate the screening
performance of measuring blood pressure and other vari-
ables in identifying those who will develop, or die from, is-
chemic heart disease and stroke and too quantify by how
much drugs that lower blood pressure will reduce the risk of is-
chemic heart disease and stroke in those designated “screen
positive.”
Data sources: Used were MEDLINE, Cochrane collaboration
and Web of Science databases; Stroke registries; Health Sur-
vey for England; Office of National Statistics; BUPA (British
United Provident Association) study.
Review methods: Relevant cohort studies and randomized
trials were identified and analyzed. Statistical analysis was
used to determine drug efficacy and adverse effects.
Results: Lowering blood pressure by 5 mm Hg diastolic re-
duces the risk of stroke by an estimated 34 percent and is-
chemic heart disease by 21 percent from any pretreatment
level; there is no threshold. These estimates, from cohort
studies, have been corroborated by the results of randomized
trials in persons with high, average, and below average levels
of blood pressure. Despite its importance in causing cardio-
vascular disease, blood pressure is a poor predictor of cardio-
vascular events. Its poor screening performance is illustrated
by the findings that, in the largest cohort study, persons in the
top 10 percent of the distribution of systolic blood pressure
experienced only 21 percent of all ischemic heart disease
events and 28 percent of all strokes at a given age. Combining
several reversible risk factors adds little to the screening per-
formance of blood pressure alone; for example, the 25 percent
of men 55–64 years of age at highest computed risk (1 per-
cent) experience only 46 percent of all ischemic heart disease
events. The main methods of screening should be to identify
all persons with a history of cardiovascular disease events (for
example, identifying patients at the time of hospital discharge
after a first myocardial infarction detects 50 percent of all
heart disease deaths in a population at a false-positive rate of
12 percent), and to use a person’s age. Identifying everyone
with a history of myocardial infarction or stroke in a population
and everyone 55 years of age or older would include 98 per-
cent of all deaths from ischemic heart disease and stroke. The
five main categories of blood pressure-lowering drugs, thi-
azides, beta-blockers, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin-II receptor antagonists, and calcium
channel blockers, significantly reduce blood pressure from all
pretreatment levels, although the extent of the blood pressure
reduction increased with pretreatment blood pressure. The
reductions were similar at standard dose for the five cate-
gories: average reduction was 9.1 systolic and 5 diastolic.
The effect of combinations of two drugs on blood pressure
was additive. No effect of age was apparent, given blood
pressure. There were no serious metabolic consequences of
using these drugs in standard dose.
Conclusions: The evidence presented indicates that three
drugs in combination may reduce stroke by approximately
two thirds and ischemic heart disease by half. The report
suggests that the term hypertension should be avoided, be-
cause it is not a disease and it suggests another category
(normotensives) who would not benefit from lowering blood
pressure. Blood pressure reduction using combinations of
safe, well-established drugs is effective in preventing cardio-
vascular events. It is, therefore, suggested that such preven-
tive therapy be considered more widely in people who, by
virtue of existing disease or simply age, are at risk of a heart
attack or stroke regardless of initial blood pressure.
Randomized controlled trial to evaluate the
clinical- and cost-effectiveness of Hickman
line insertions in adult cancer patients by
nurses
A. Boland, A. Haycox, A. Bagust, University of Liverpool; and
L. Fitzsimmons, Christie Hospital NHS Trust
Objectives: This study examined the clinical- and cost-
effectiveness of image-guided Hickman line insertions versus
blind Hickman line insertions undertaken by nurses in adult
cancer patients.
Design: A cost-effectiveness analysis was carried out along-
side a randomized controlled trial.
Setting: The study was undertaken at a large acute cancer
center in Manchester, United Kingdom.
Participants: Cancer patients due to have a Hickman line
insertion who were older than 18 years of age and were clini-
cally and physically compliant with specified protocols partic-
ipated.
Interventions: To obtain central venous access for the pa-
tient, two interventions were investigated: (i) blind insertion of
a Hickman line and (ii) image-guided insertion of a Hickman
line. Both interventions involved blind venipuncture of the sub-
clavian vein. In the blind arm, the Hickman line was routinely
inserted without the use of image guidance at any point in
the procedure. Transfer to the interventional X-ray suite and
use of image guidance were options immediately available to
the operator during the procedure if required. In the image-
guided arm, the position of the guidewire was checked before
the Hickman line was introduced and later the Hickman line
was positioned with the use of X-ray fluoroscopy.
Main outcome measures: The primary clinical outcome
measure was catheter-tip misplacement, and this misplace-
ment was expected to be higher in the blind arm. When com-
paring the skill level of the trainer and the trainees, pneu-
mothorax was the primary clinical outcome measure. Other
outcomes measures included arterial puncture, hematoma,
infection, failed insertion, and assistance from other health-
care professionals.
Results: No statistically significant difference was found be-
tween the mean cost per patient in the two arms of the trial.
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The only statistically significant difference in clinical outcomes
was the frequency of catheter-tip misplacement, which was
higher in the blind arm of the trial. At very low costs, the image-
guided approach dominates the blind approach as fewer costs
and greater benefits are incurred. It is evident that nurses
previously inexperienced in the procedure can be trained to
insert Hickman lines successfully both at the bedside and
under image guidance within a 3-month period.
Conclusions: This report indicates that nurse insertion of
Hickman lines in the majority of adult cancer patients is both
safe and effective. However, there are a select group of pa-
tients for whom image-guided insertion may be preferred.
The results reveal that skills and expertise can be transferred
from trainer to trainee through a relatively short, but inten-
sive, training course. It is also evident that patients support
nurse insertion. Further research is suggested to compare
the safety and efficacy of nurse versus doctor insertions in
particular subgroups of patients and also to assess the quan-
tity and quality of current service provision to inform National
Health Service decision-making in this area.
Systematic review of isolation policies in
the hospital management of methicillin-
resistant Staphylococcus aureus: A review
of the literature with epidemiological and
economic modeling
B. S. Cooper, S. P. Stone, C. C. Kibbler, B. D. Cookson, J. A.
Roberts, University of London; G. F. Medley, University of
Warwick; G. J. Duckworth, Communicable Disease Surveil-
lance Centre; R. Lai, University of London; and S. Ebrahim,
University of Bristol
Objectives: This study reviewed the evidence for the effec-
tiveness of different isolation policies and screening practices
in reducing the incidence of methicillin-resistant Staphylococ-
cus aureus (MRSA) colonization and infection in hospital in-
patients in an effort to develop transmission models to study
the effectiveness and cost-effectiveness of isolation policies
in controlling MRSA.
Data sources: Sources included MEDLINE, EMBASE,
CINAHL, The Cochrane Library, and SIGLE (1966–2000), as
well as handsearching key journals. No language restrictions
were used.
Review methods: Key data were extracted from articles re-
porting MRSA-related outcomes and describing an isolation
policy in a hospital with epidemic or endemic MRSA. No qual-
ity restrictions were imposed on studies using isolation wards
(IW) or nurse cohorting (NC). Other studies were included if
they were prospective or used planned comparisons of ret-
rospective data. Stochastic and deterministic models inves-
tigated long-term transmission dynamics, studying the effect
of a fixed capacity IW, producing economic evaluations using
local cost data.
Results: A total of forty-six studies were accepted: eighteen
IWs, nine NC, nineteen other isolation policies. Most were
interrupted time series, with few planned formal prospective
studies. All but one reported multiple interventions. Consider-
ation of potential confounders, measures to prevent bias, and
appropriate statistical analysis were mostly lacking. No con-
clusions could be drawn in a third of the studies. Most others
provided evidence consistent with reduction of MRSA acqui-
sition. Six long interrupted time series provided the strongest
evidence. Four of these studies provided evidence that in-
tensive control measures that included patient isolation were
effective in controlling MRSA. In two others, IW use failed to
prevent endemic MRSA. There was no robust economic eval-
uation. Models showed that improving the detection rate or
ensuring adequate isolation capacity reduced endemic levels,
with substantial savings achievable.
Conclusions: Major methodological weaknesses and inade-
quate reporting in published research mean that many plau-
sible alternative explanations for reductions in MRSA acqui-
sition associated with interventions cannot be excluded. No
well-designed studies allow the role of isolation measures
alone to be assessed. Nonetheless, there is evidence that
concerted efforts that include isolation can reduce MRSA
even when endemic. Little evidence was found to suggest
that current isolation measures recommended in the United
Kingdom are ineffective, and these practices should continue
to be applied until further research establishes otherwise. The
studies with the strongest evidence, together with the results
of the modeling, provide testable hypotheses for future re-
search. Guidelines to facilitate design of future research are
produced.
Routine examination of the newborn: The
EMREN study. Evaluation of an extension
of the midwife role including a randomized
controlled trial of appropriately trained
midwives and pediatric senior house
officers
J. Townsend, London School of Hygiene and Tropical Medi-
cine; D. Wolke, J. Hayes, S. Dave´, C. Rogers, L. Bloomfield,
University of Hertfordshire; E. Quist-Therson, Mount Vernon
and Watford Hospitals NHS Trust; M. Tomlin, and D. Messer,
University of Hertfordshire
Objectives: This study assesses the implications and cost-
effectiveness of extending the role of midwives to include the
routine (24-hour) examination of the healthy newborn usually
carried out by junior doctors.
Design: The study included a prospective randomized con-
trolled trial (RCT) with mother and baby dyads randomized
to either senior house officer (SHO) or midwife for the rou-
tine examination of the newborn. Midwives and SHOs were
also video taped while performing the examinations, and the
videos were rated by an independent consultant and senior
midwife. In addition, extensive interviews, surveys, consulta-
tions, and assessments were carried out.
Setting: Several settings were involved, including a district
general hospital (for the RCT), a London teaching hospital,
general practices, and mothers’ homes (for interviews). Ques-
tionnaires were sent to all maternity units in England (for the
National Survey).
Participants: A total of 826 mother and baby dyads in a
District General Hospital in southeast England participated.
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Midwives and SHOs, as well as midwifery managers, pediatric
consultants; general practitioners (GPs) and representatives
of key organizations also participated.
Interventions: A routine examination of a newborn baby
was carried out at approximately 24 hours from birth, and
another examination for half the babies in each group was
carried out at 10 days at home by the community mid-
wife.
Main outcome measures: Referrals were assessed as ap-
propriate and as major or minor by three independent consul-
tants. Problems identified during the first year of life were as-
sessed as identifiable at 24 hours. Other measures included
quality assessment by video against an agreed written pro-
forma, maternal satisfaction, and opinion of professionals and
mothers about aspects of the examination.
Results: There was no statistical difference between SHO
and midwife examinations in appropriate referral rates to hos-
pital or community or in inappropriate referral rates to hospi-
tal. Video taped assessments were assessed to be carried
out more appropriately by the midwives than by the SHOs.
Overall, maternal satisfaction was high and higher when a
midwife rather than an SHO was involved. Few new health
problems were identified at the 10-day examination. From the
National Survey, it was estimated that approximately 2 per-
cent of babies in England are examined by a midwife. If mid-
wives were to examine all babies where there were no com-
plications of birth or antenatal history, there would be savings
of approximately £2 per baby born, equivalent to savings of
£1.2 million nationally. Were midwives to examine all babies
on normal wards, savings would increase to approximately
£4.30 per baby born or £2.5 million nationally. Representa-
tives of the professional bodies were of the opinion that hav-
ing trained midwives carrying out the examination would be
valuable.
Conclusions: All component aspects of the study were con-
sistent in showing benefits or at least no significant barriers
to suitably qualified, trained midwives carrying out the exam-
inations. Developing the role of the midwife to include exam-
ination of the newborn is likely to result in improved qual-
ity of examinations and higher satisfaction from mothers. It
would slightly reduce overall health service costs, with some
increased resources needed by midwifery departments and
some decrease in resource needs of pediatric departments.
There is a need for further research into the value of the ex-
amination being carried out at home rather than in a hospital,
the overall unsatisfactory quality of the examination of the
hips, and appropriate inclusion criteria for which babies the
midwives should examine.
Impact of screening on future
health-promoting behaviors and health
beliefs: A systematic review
C. R. Bankhead, J. Brett, C. Bukach, P. Webster, Oxford
University; S. Stewart-Brown, The University of Warwick; M.
Munafo, Oxford University, Radcliffe Infirmary; and J.
Austoker, Oxford University
Objectives: A systematic review was performed to examine
the effects of cholesterol, breast cancer, and cervical cancer
screening on actual or intended health-promoting behaviors
and health-related beliefs.
Methods: Eleven electronic databases (between 1980 and
2000) served as data sources. All English language stud-
ies that investigated the impact of cholesterol, breast, and
cervical screening programs on health-promoting behaviors
and beliefs were assessed for inclusion. The data extraction
form and quality assessment criteria were developed using
the National Health Service Centre for Reviews and Dissem-
ination guidelines. Data were extracted, and a nonquanti-
tative synthesis was conducted. Reviewers categorized the
outcomes into those that could be considered beneficial or
detrimental to health. This categorization was based on a
value judgment that considered both statistical and clinical
significance.
Results: The cholesterol studies used prospective designs
more frequently, possibly as many investigators focused on
observing changes in lifestyle after screening. Participants
who went for breast or cervical screening were not offered
advice on lifestyle changes, and most of the research into
cancer screening programs investigated issues related to
uptake of screening services, explanations of why people
are or are not screened, and interventions to improve uptake.
All three screening programs are associated with high levels
of favorable health behaviors and beliefs that have been mea-
sured, although there is evidence that recommended follow-
up after screening is often not adhered to. There was no
literature on the cost-effectiveness regarding the wider im-
plications of screening (only on reduction of disease-specific
mortality/morbidity), possibly due to the outcomes being very
broad and not easily categorized and classified.
Conclusions: The studies reviewed suggest that cholesterol
screening had a positive effect on health behaviors, although
participation was voluntary and those screened were possi-
bly more motivated to make changes. These results, there-
fore, are not generalizable to the entire population, and other
factors need to be taken into account. Reduction in blood
cholesterol levels was reported in all but two of the stud-
ies that assessed this outcome, suggesting that success-
ful lifestyle changes were made. However, as most of the
studies only reported follow-up of those screened, some of
the reduction can be attributable to regression to the mean.
Whether breast and cervical screening affect future health be-
haviors and beliefs has not been directly measured in many
studies, and few studies have collected baseline measures.
However, evidence suggests that women who attend breast
and cervical screening once are likely to reattend, and at-
tendance is associated with several positive health behav-
iors, although it cannot be confirmed whether the associa-
tions observed were a result of screening or because these
women have a certain set of health behaviors and beliefs
irrespective of their experience of screening. Areas of fur-
ther research include measuring a much wider range of be-
haviors and beliefs before and after screening is accepted
or declined, examining the subgroup of participants who re-
ceive “desirable” results and the impact of this on health be-
liefs and health-promoting behavior, and qualitative research
into the experiences of screening and how this finding in-
teracts with knowledge and beliefs about other aspects of
health.
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What is the best imaging strategy for acute
stroke?
J. M. Wardlaw, S. L. Keir, Western General Hospital (Uni-
versity of Edinburgh); J. Seymour, University of Aberdeen
S. Lewis, P. A. G. Sandercock, M. S. Dennis, Western General
Hospital (University of Edinburgh); and J. Cairns, University
of Aberdeen
Objectives: The cost-effectiveness of computed tomographic
(CT) scanning after acute stroke was investigated to assess
the contribution of brain imaging to the diagnosis and mana-
gement of stroke and to estimate the costs, benefits, and
risks of different imaging strategies to provide data to inform
national and local policy on the use of brain imaging in stroke.
Methods: A decision-analysis model was developed to rep-
resent the pathway of care in acute stroke, using “scan all
patients within 48 hours” as the comparator against twelve
alternative scan strategies. Hospitals in Scotland were the
setting. The participants were patients admitted to the hos-
pital with a first stroke and those managed as outpatients.
The interventions included the effect on functional outcome
after ischemic or hemorrhagic stroke, tumors, or infections
of correctly administered antithrombotic or other treatment;
of time to scan and stroke severity on diagnosis by CT or
magnetic resonance imaging (MRI); on management, includ-
ing length of stay, functional outcome, and quality-adjusted
life years (QALYs) of the diagnostic information provided by
CT scanning; and the cost-effectiveness (cost versus QALYs)
of different strategies for use of CT after acute stroke. The
main outcome measures were death and functional outcome
at long-term follow-up; accuracy of CT and MRI; cost of CT
scanning by time of day and week; effect of CT diagno-
sis on change in health outcome, length of stay in hospital,
and QALYs; and cost-effectiveness of various scanning
strategies.
Results: CT is very sensitive and specific for hemorrhage
within the first 8 days of stroke only. Suboptimal scanning
used in epidemiology studies suggests that the frequency of
primary intracerebral hemorrhage (PICH) has been underes-
timated. Aspirin increases the risk of PICH. There were no
reliable data on functional outcome or on the effect of an-
tithrombotic treatment given long-term after PICH. In 60 per-
cent of patients with recurrent stroke after PICH, the cause is
another PICH and mortality is high among PICH patients. A
specific MR sequence (gradient echo) is required to identify
prior PICH reliably. CT scanners were distributed unevenly in
Scotland, 65 percent provided CT scanning within 48 hours
of stroke, and 100 percent within 7 days for hospital-admitted
patients, but access after hours was very variable and for
outpatients was poor. The average cost of a CT brain scan
for stroke was £30.23 to £89.56 in normal working hours and
£55.05 to £173.46 after hours. Average length of stay was
greatest for severe strokes and those who survived in a de-
pendent state. For a cohort of 1,000 patients 70–74 years
of age, the policy “scan all strokes within 48 hours,” cost
£10,279,728 and achieved 1982.3 QALYS. The most cost-
effective strategy was “scan all immediately” (£9,993,676 and
1982.4 QALYS). The least cost-effective was to “scan patients
on anticoagulants, in a life-threatening condition immediately
and the rest within 14 days.”
Conclusions: In general, strategies in which most patients
were scanned immediately cost least and achieved the most
QALYs, as the cost of providing CT (even after hours) was
less than the cost of inpatient care. Increasing independent
survival by even a small proportion through early use of as-
pirin in the majority with ischemic stroke, avoiding aspirin in
those with hemorrhagic stroke, and appropriate early man-
agement of those who have not had a stroke, reduced costs
and increased QALYs.
Systematic review and modeling of the
investigation of acute and chronic chest
pain presenting in primary care
J. Mant, R. J. McManus, R. A. L. Oakes, B. C. Delaney,
University of Birmingham; P. M. Barton, University of
Birmingham; J. J. Deeks, Institute of Health Sciences;
L. Hammersley, University of Birmingham; R. C. Davies,
Sandwell and West Birmingham NHS Trust, Sandwell Gene-
ral Hospital; M. K. Davies, University Hospital, Birmingham
NHS Trust; and F. D. R. Hobbs, University of Birmingham
Objectives: The objectives were to ascertain the value of
a range of methods—including clinical features, resting and
exercise electrocardiography, and rapid access chest pain
clinics (RACPCs)—used in the diagnosis and early manage-
ment of acute coronary syndrome (ACS), suspected acute
myocardial infarction (MI), and exertional angina.
Methods: MEDLINE, EMBASE, CINAHL, the Cochrane Li-
brary, and electronic abstracts of recent cardiological con-
ferences were used as data sources. Searches identified
studies that considered patients with acute chest pain with
data on the diagnostic value of clinical features or an electro-
cardiogram (ECG) and patients with chronic chest pain with
data on the diagnostic value of resting or exercise ECG or
the effect of a RACPC. Likelihood ratios (LRs) were calcu-
lated for each study, and pooled LRs were generated with
95 percent confidence intervals. A Monte Carlo simulation
was performed evaluating different assessment strategies
for suspected ACS, and a discrete event simulation eval-
uated models for the assessment of suspected exertional
angina.
Results: For acute chest pain, no clinical features in isolation
were useful in ruling in or excluding an ACS, although the
most helpful clinical features were pleuritic pain (LR + 0.19)
and pain on palpation (LR + 0.23). ST elevation was the most-
effective ECG feature for determining MI (with LR + 13.1) and
a completely normal ECG was reasonably useful at ruling
out this condition (LR + 0.14). Results from “black box” stud-
ies of clinical interpretation of ECGs found very high speci-
ficity but low sensitivity. In the simulation exercise of manage-
ment strategies for suspected ACS, the point of care testing
with troponins was cost-effective. Prehospital thrombolysis
on the basis of ambulance telemetry was more effective but
more costly than if performed in the hospital. In cases of
chronic chest pain, resting ECG features were not found to
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be very useful (presence of Q-waves had LR + 2.56). For an
exercise ECG, ST depression performed only moderately well
(LR + 2.79 for a 1-mm cutoff), although this performance did
improve for a 2-mm cutoff (LR + 3.85). Other methods of
interpreting the exercise ECG did not result in dramatic im-
provements in these results. Weak evidence was found to
suggest that RACPCs may be associated with reduced ad-
mission to hospital of patients with noncardiac pain, bet-
ter recognition of ACS, earlier specialist assessment of ex-
ertional angina and earlier diagnosis of noncardiac chest
pain. In a simulation exercise of models of care for inves-
tigation of suspected exertional angina, RACPCs were pre-
dicted to result in earlier diagnosis of both confirmed coro-
nary heart disease (CHD) and noncardiac chest pain than
models of care based around open access exercise tests
or routine cardiology outpatients, but they were more ex-
pensive. The benefits of RACPCs disappeared if waiting
times for further investigation (e.g., angiography) were long
(6 months).
Conclusions: Where an ACS is suspected, emergency re-
ferral is justified. ECG interpretation in acute chest pain can
be highly specific for diagnosing MI. Point of care testing
with troponins is cost-effective in the triaging of patients
with suspected ACS. Resting ECG and exercise ECG are
of only limited value in the diagnosis of CHD. The poten-
tial advantages of RACPCs are lost if there are long waiting
times for further investigation. Recommendations for further
research include the following: determining the most appro-
priate model of care to ensure accurate triaging of patients
with suspected ACS; establishing the cost-effectiveness of
prehospital thrombolysis in rural areas; determining the rela-
tive cost-effectiveness of rapid access chest pain clinics com-
pared with other innovative models of care; investigating how
rapid access chest pain clinics should be managed; and es-
tablishing the long-term outcome of patients discharged from
RACPCs.
Effectiveness and efficiency of guideline
dissemination and implementation
strategies
J. M. Grimshaw, R. E. Thomas, G. MacLennan, C. Fraser,
C.R. Ramsay, L. Vale, University of Aberdeen; P. Whitty,
M. P. Eccles, University of Newcastle upon Tyne; L. Matowe,
L. Shirran, University of Aberdeen; M. Wensing, R. Dijkstra,
University of Nijmegen; and C. Donaldson, University of
Calgary
Objectives: A systematic review of the effectiveness and
costs of different guideline development, dissemination, and
implementation strategies was undertaken. The resource im-
plications of these strategies was estimated, and a framework
for deciding when it is efficient to develop and introduce clini-
cal guidelines was developed.
Methods: MEDLINE, Healthstar, Cochrane Controlled Trial
Register, EMBASE, SIGLE, and the specialized register of
the Cochrane Effective Practice and Organization of Care
(EPOC) group were used as data sources. Single estimates
of dichotomous process variables were derived for each study
comparison based upon the primary end point or the median
measure across several reported end points. Separate anal-
yses were undertaken for comparisons of different types of
intervention. The study also explored whether the effects of
multifaceted interventions increased with the number of inter-
vention components. Studies reporting economic data were
also critically appraised. A survey to estimate the feasibility
and likely resource requirements of guideline dissemination
and implementation strategies in United Kingdom settings
was carried out with key informants from primary and sec-
ondary care.
Results: In total, 235 studies reporting 309 comparisons
met the inclusion criteria; of these studies, 73 percent of
comparisons evaluated multifaceted interventions, although
the maximum number of replications of a specific multi-
faceted intervention was eleven comparisons. Overall, the
majority of comparisons reporting dichotomous process data
observed improvements in care; however, there was con-
siderable variation in the observed effects both within and
across interventions. Commonly evaluated single interven-
tions were reminders, dissemination of educational materi-
als, and audit and feedback. There were twenty-three com-
parisons of multifaceted interventions involving educational
outreach. The majority of interventions observed modest to
moderate improvements in care. No relationship was found
between the number of component interventions and the ef-
fects of multifaceted interventions. Only 29.4 percent of com-
parisons reported any economic data. The majority of stud-
ies only reported costs of treatment; only twenty-five stud-
ies reported data on the costs of guideline development or
guideline dissemination and implementation. The majority of
studies used process measures for their primary end point,
despite that only three guidelines were explicitly evidence-
based (and may not have been efficient). Respondents to
the key informant survey rarely identified existing budgets to
support guideline dissemination and implementation strate-
gies. In general, the respondents thought that only dissem-
ination of educational materials and short (lunchtime) ed-
ucational meetings were generally feasible within current
resources.
Conclusions: There is an imperfect evidence base to
support decisions about which guideline dissemination and
implementation strategies are likely to be efficient under
different circumstances. Decision-makers need to use con-
siderable judgment about how best to use the limited re-
sources they have for clinical governance and related ac-
tivities to maximize population benefits. They need to con-
sider the potential clinical areas for clinical effectiveness
activities, the likely benefits and costs required to intro-
duce guidelines and the likely benefits and costs as a re-
sult of any changes in provider behavior. Further research
is required to develop and validate a coherent theoretical
framework of health professional and organizational be-
havior and behavior change to inform better the choice of
interventions in research and service settings and to es-
timate the efficiency of dissemination and implementation
strategies in the presence of different barriers and effect
modifiers.
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Technology assessment reports
Clinical-effectiveness and
cost-effectiveness of neonatal screening
for inborn errors of metabolism using
tandem mass spectrometry: A systematic
review
A. Pandor, The University of Sheffield; J. Eastham, University
of Leeds; C. Beverley, J. Chilcott, S. Paisley, The University
of Sheffield
Objectives: The clinical- and cost-effectiveness of tandem
mass spectrometry (MS)-based neonatal screening for inborn
errors of metabolism (IEM) were evaluated.
Methods: Fourteen electronic bibliographic databases cov-
ering biomedical, science, economic, and gray literature; the
reference lists of relevant articles and abstracts of conference
proceedings; and eighteen health services research-related
resources served as data sources. This review is an update of
two previous health technology assessment reports of neona-
tal screening for IEM. These reports have been updated by a
systematic review of published research (between 1995 and
January 2002) on neonatal screening of inherited metabolic
disorders using tandem MS. This update was supplemented
by a search for economic literature and the application of a
modeling exercise to investigate the economics of using tan-
dem MS within a neonatal screening program in the United
Kingdom.
Results: Evidence from the reviews of IEM found that
the UK screening program for phenylketonuria (PKU) was
well established and that there was universal agreement
that neonatal screening for PKU was justified. Of the many
other disorders that can be detected by tandem MS, the
best candidate condition for a new screening program was
medium-chain acyl-coenzyme A dehydrogenase (MCAD) de-
ficiency. For many other IEM that can be detected by tandem
MS, robust clinical evidence was limited. Cost-effectiveness
analysis using economic modeling indicated that substituted
the use of tandem MS for existing technologies for the
screening of PKU alone could not be justified. However, re-
sults from the economic modeling indicated that the addi-
tion of screening for MCAD deficiency as part of a neona-
tal screening program for PKU using tandem MS would
be economically attractive. Using an operational range of
50,000–60,000 specimens per system per year, the mean
incremental cost for PKU and MCAD deficiency screening
combined using tandem MS from the model was −£23,312
for each cohort of 100,000 neonates screened. This cost
saving is associated with a mean incremental gain of 59
life-years. Additional economic modeling using the avail-
able evidence does not support including other inherited
metabolic diseases within a neonatal screening program at
present.
Conclusions: The evidence appears to support the intro-
duction of tandem MS into a UK neonatal screening program
for PKU and MCAD deficiency combined. Tandem MS has
the potential for simultaneous multi-disease screening using
a single analytical technique. Although the marginal cost of
extending the program to include other conditions may be rel-
atively small, the application of this new technology to PKU
and MCAD deficiency screening does not suggest the whole-
sale inclusion of all disorders detectable by tandem MS. It is
suggested that the primary focus of further research should
be on the long-term effectiveness of treatment strategies on
adverse outcomes (disabilities and impairments) under con-
ventional management and the potential impact of early di-
agnosis using tandem MS.
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